Ask AI
ProCE Banner Activity

No Pain, No Gain? Why Injection-Site Reactions Should Not Deter Us From Appropriate Use of Long-Acting ART

Clinical Thought

Injection-site reactions (ISRs) with long-acting (LA) antiretroviral therapy (ART) for HIV are common and expected, but manageable, and they should be considered in the context of the overall benefit of LA ART for treatment or prevention. Here’s how I counsel patients on what to expect and why I consider effective counseling to be the most important intervention for improving tolerability of ISRs with LA ART.

Released: August 11, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from ViiV Healthcare.

ViiV Healthcare

Target Audience

This activity is intended for physicians, registered nurses, pharmacists, and other healthcare professionals who provide care with long-acting agents to people living with HIV and people who can benefit from PrEP.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Gain a deep evidence-informed understanding of ISRs associated with LA agents, including their frequency, characteristics, expected course, and differences across agents

  • Engage people who can benefit from LA ART agents in informed, evidence-based, and individualized shared decision-making that incorporates accurate discussion about ISRs

Financial Disclosures

Primary Author

Monica Gandhi, MD, MPH, has no relevant financial relationships to disclose.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.